Table 3.
Bivariate analyses between clusters SV1, SV2, and SV3 upon SEB stimulation and clinical and biological parameters.
| Cluster SV1 (n = 11) | Cluster SV2 (n = 14) | Cluster SV3 (n = 15) | p value | |
|---|---|---|---|---|
| Status | < 0.001 | |||
| Healthy, n (%) | 10 (91) | 0 (0) | 0 (0) | |
| Sepsis patients, n (%) | 0 (0) | 6 (43) | 4 (27) | |
| Septic shock patients, n (%) | 1 (8) | 8 (57) | 11 (73) | |
| Comorbidities*,a | 0.427 | |||
| No, n (%) | 0 (0) | 5 (35.7) | 3 (20) | |
| Yes, n (%) | 1 (100) | 9 (64.3) | 12 (80) | |
| Day 1 | ||||
| Median SOFA*, [IQR] | 8 | 9 [8–9.8] | 9 [4.5–10.5] | 0.335 |
| Day 3–4 | ||||
| Median mHLA-DR (Ab/C), [IQR] | 28,272 [18308–30940] | 5098 [3544–8223] | 4680 [3097–8709] | < 0.001 |
| Median TNFα secretion post-LPS stimulation (pg/mL), [IQR] | 4176 [3644–5412] | 1590 [1289–2442] | 719 [474–1090] | < 0.001 |
| Outcomes | ||||
| Hospital-acquired infections*, n (%) | 0 (0) | 1 (7.1) | 7 (46.7) | 0.035 |
| Median ICU length of stay*, [IQR] | 2 | 7.5 [5–9.8] | 11 [7–16] | 0.050 |
| Mortality at day 28*, n (%) | 0 (0) | 3 (21.4) | 0 (0) | 0.053 |
For categorical variables Chi-squared test was used and for numerical variables, t test (parametric) or Wilcoxon (non-parametric) was used.
SOFA sequential organ failure assessment, ICU intensive care unit, HLA-DR human leukocyte antigen DR, TNFα tumour necrosis factor alpha, LPS lipopolysaccharide.
*Parameters measured exclusively for septic patients.
aPresence of comorbidities was affirmative when at least one of the following comorbidity was present in the patient: chronic pulmonary disease, heart failure, myocardial infarction, ulcer, diabetes, renal failure, or malign solid tumour.